MA28908B1 - HUMAN GROWTH HORMONE CONJUGATES WITH GLYCEROL BRANCHED POLYETHYLENE GLYCOL, PROCESS FOR THEIR PREPARATION AND METHODS FOR THEIR USE - Google Patents

HUMAN GROWTH HORMONE CONJUGATES WITH GLYCEROL BRANCHED POLYETHYLENE GLYCOL, PROCESS FOR THEIR PREPARATION AND METHODS FOR THEIR USE

Info

Publication number
MA28908B1
MA28908B1 MA29724A MA29724A MA28908B1 MA 28908 B1 MA28908 B1 MA 28908B1 MA 29724 A MA29724 A MA 29724A MA 29724 A MA29724 A MA 29724A MA 28908 B1 MA28908 B1 MA 28908B1
Authority
MA
Morocco
Prior art keywords
preparation
methods
polyethylene glycol
growth hormone
human growth
Prior art date
Application number
MA29724A
Other languages
French (fr)
Inventor
Rory F Finn
Ned R Siegel
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28908(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of MA28908B1 publication Critical patent/MA28908B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA29724A 2004-08-31 2007-02-28 HUMAN GROWTH HORMONE CONJUGATES WITH GLYCEROL BRANCHED POLYETHYLENE GLYCOL, PROCESS FOR THEIR PREPARATION AND METHODS FOR THEIR USE MA28908B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60594504P 2004-08-31 2004-08-31

Publications (1)

Publication Number Publication Date
MA28908B1 true MA28908B1 (en) 2007-10-01

Family

ID=35708806

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29724A MA28908B1 (en) 2004-08-31 2007-02-28 HUMAN GROWTH HORMONE CONJUGATES WITH GLYCEROL BRANCHED POLYETHYLENE GLYCOL, PROCESS FOR THEIR PREPARATION AND METHODS FOR THEIR USE

Country Status (24)

Country Link
EP (1) EP1789092A2 (en)
JP (1) JP2008511610A (en)
KR (1) KR20070042567A (en)
CN (1) CN101010105A (en)
AP (1) AP2007003919A0 (en)
AR (1) AR050851A1 (en)
AU (1) AU2005278903A1 (en)
BR (1) BRPI0515118A (en)
CA (1) CA2577999A1 (en)
CR (1) CR8942A (en)
EA (1) EA200700380A1 (en)
EC (1) ECSP077281A (en)
GT (1) GT200500235A (en)
IL (1) IL181085A0 (en)
MA (1) MA28908B1 (en)
MX (1) MX2007002441A (en)
NL (1) NL1029828C2 (en)
NO (1) NO20071322L (en)
PE (1) PE20060654A1 (en)
TN (1) TNSN07078A1 (en)
TW (1) TW200621291A (en)
UY (1) UY29088A1 (en)
WO (1) WO2006024953A2 (en)
ZA (1) ZA200701802B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
AU751898B2 (en) 1997-07-14 2002-08-29 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
IL144259A0 (en) 1999-01-14 2002-05-23 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
WO2007132956A1 (en) * 2006-05-12 2007-11-22 Dong-A Pharm.Co., Ltd. Polyethylene glycol-interferon alpha conjugate
JP2008069073A (en) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd Lactoferrin conjugate and its manufacturing method
KR101079993B1 (en) 2006-11-17 2011-11-04 동아제약주식회사 Polyethylene glycol-G-CSF conjugate
CL2008002399A1 (en) 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
TWI388570B (en) * 2008-07-23 2013-03-11 Hanmi Science Co Ltd A polypeptide complex comprising non-peptidyl polymer having three functional ends
AR072850A1 (en) 2008-07-31 2010-09-22 Pharmaessentia Corp PEPTIDO-POLYMER CONJUGATES
WO2010040187A1 (en) 2008-10-10 2010-04-15 The Bionic Ear Institute Polymer-bioactive agent conjugates
DK2355853T3 (en) * 2008-10-10 2017-03-06 Polyactiva Pty Ltd BIODEGRADABLE POLYMER-BIOACTIVE FRAGMENT CONJUGATES
US8535655B2 (en) 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
DK3178835T3 (en) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc EXTENDED RECOMBINANT POLYPEPTIDES AND COMPOSITIONS INCLUDING THE SAME
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
JP6086528B2 (en) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Growth hormone with long-term in vivo efficacy
CN101831067A (en) * 2010-05-31 2010-09-15 王二新 Polyethylene glycol ester conjugate and application thereof in medicine preparation
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
CN102367290B (en) * 2011-04-26 2013-05-08 厦门赛诺邦格生物科技有限公司 Chain-functionalized multi-level branched polyethylene glycol and synthesis method thereof
EP2947111B1 (en) * 2013-01-17 2018-03-07 Xiamen Sinopeg Biotech Co., Ltd. Monofunctional branched polyethyleneglycol and bio-related substance modified by same
CN104877127B (en) 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 A kind of eight arms polyethyleneglycol derivative, preparation method and its bio-related substance of modification
MY191506A (en) 2014-11-06 2022-06-28 Pharmaessentia Corp Dosage regimen for pegylated interferon
CN111741770A (en) * 2017-12-29 2020-10-02 豪夫迈·罗氏有限公司 Methods for providing pegylated protein compositions
HRP20220041T1 (en) 2017-12-29 2022-04-15 F. Hoffmann - La Roche Ag Process for providing pegylated protein composition
ES2909454T3 (en) * 2017-12-29 2022-05-06 Hoffmann La Roche Procedure for Providing a PEGylated Protein Composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2147192A (en) * 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
JP3092531B2 (en) * 1996-11-05 2000-09-25 日本油脂株式会社 Method for producing imidyl succinate-substituted polyoxyalkylene derivative
AU751898B2 (en) * 1997-07-14 2002-08-29 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
JP3921781B2 (en) * 1998-02-12 2007-05-30 日本油脂株式会社 Carboxyl group-containing polyoxyalkylene compound
IL144259A0 (en) * 1999-01-14 2002-05-23 Bolder Biotechnology Inc Methods for making proteins containing free cysteine residues
BR0214451A (en) * 2001-11-20 2006-05-30 Pharmacia Corp chemically modified human growth hormone conjugates
KR20050093856A (en) * 2002-09-09 2005-09-23 넥타르 테라퓨틱스 에이엘, 코포레이션 Water-soluble polymer alkanals
JP4412461B2 (en) * 2002-11-20 2010-02-10 日油株式会社 Modified bio-related substance, production method thereof and intermediate
KR101090784B1 (en) * 2002-12-31 2011-12-08 넥타르 테라퓨틱스 Polymeric reagents comprising a ketone or a related functional group
KR101128320B1 (en) * 2003-05-23 2012-04-12 넥타르 테라퓨틱스 Peg derivatives having an amidocarbonate linkage

Also Published As

Publication number Publication date
CR8942A (en) 2007-08-16
PE20060654A1 (en) 2006-08-12
NL1029828C2 (en) 2006-10-20
ZA200701802B (en) 2008-08-27
WO2006024953A3 (en) 2007-01-18
JP2008511610A (en) 2008-04-17
EA200700380A1 (en) 2007-10-26
NL1029828A1 (en) 2006-03-01
TW200621291A (en) 2006-07-01
KR20070042567A (en) 2007-04-23
UY29088A1 (en) 2006-03-31
CN101010105A (en) 2007-08-01
IL181085A0 (en) 2007-07-04
NO20071322L (en) 2007-05-29
TNSN07078A1 (en) 2008-06-02
AR050851A1 (en) 2006-11-29
MX2007002441A (en) 2007-05-04
AP2007003919A0 (en) 2007-02-28
EP1789092A2 (en) 2007-05-30
ECSP077281A (en) 2007-03-29
AU2005278903A1 (en) 2006-03-09
BRPI0515118A (en) 2008-07-01
GT200500235A (en) 2006-03-21
WO2006024953A2 (en) 2006-03-09
CA2577999A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
MA28908B1 (en) HUMAN GROWTH HORMONE CONJUGATES WITH GLYCEROL BRANCHED POLYETHYLENE GLYCOL, PROCESS FOR THEIR PREPARATION AND METHODS FOR THEIR USE
NL1028837A1 (en) N-terminal mono-pegylated human growth hormone conjugates and process for their preparation.
EP1720575A4 (en) Therapeutic and diagnostic conjugates for use with multispecific antibodies
DE60004624D1 (en) Device for fundus photography
DK1631211T3 (en) Apparatus for the prevention of urinary incontinence in women
MA28757B1 (en) ANTIBODIES AGAINST THE AMYLOID-BETA PEPTIDE AND METHODS FOR THEIR USE
EP3281956A3 (en) Human antibody drug conjugates against tissue factor
FR2869217B1 (en) GLENOIDAL IMPLANT FOR TOTAL REVERSE SHOULDER PROSTHESIS, AND TOTAL REVERSE SHOULDER PROSTHESIS COMPRISING THE SAME
MA28337A1 (en) 7-PHENYLAMINO-4-QUINOLONE-3-CARBOXYLIC ACID DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS
EP2330833A3 (en) Cell selection method and mobile station
IL183582A0 (en) Polymer conjugates and methods for the preparation thereof
DE60131760D1 (en) DEVICE FOR THE ADMINISTRATION OF PHYSIOLOGICALLY ACTIVE ACTIVE IN POWDER FORM
IL176836A (en) Substituted phenoxy- and phenylthio-derivatives and intermediates thereof, process for the preparation thereof, pharmaceutical compositions comprising same, conjugates including same and use thereof
FI20041704A0 (en) Stable microbial inoculants and processes for their preparation
EP1820852A4 (en) Human serum for cell culture
ITMI20042473A1 (en) SYSTEM FOR PERFORMING QUICK CHECKS DURING THE CONFIGURATION OF FLASH REFERENCE CELLS
IS8428A (en) Infusion containing (2R) -2-propyl octanoic acid as the active ingredient
WO2008110392A3 (en) Biopsy device for the in vivo enrichment of tissue, cells, or analytes
DE60234250D1 (en) Device for cell or tissue culture
WO2006039631A3 (en) Methods and compositions for treating renal cell carcinoma related pathologies
ITMI20001848A0 (en) DRUGS FOR INCONTINENCE.
FR2862965B1 (en) NOVEL PHENOXYACETAMIDE DERIVATIVES AND THEIR USE FOR THE PREPARATION OF DIPHENYLAMIDES.
FR2873587B1 (en) APPARATUS FOR DIFFUSION OF ACTIVE COMPOUNDS IN THE ATMOSPHERE
FR2874811B1 (en) ANTIPHOTOPHOBIC OCULAR DEVICE AND METHOD FOR PREPARING THE SAME
DE602006002328D1 (en) Polysubstituted 1,1-pyridinyloxycyclopropanamine derivatives, processes for their preparation and the pharmaceutical compositions containing them